Breakthrough Approval for AK112: Akeso Biopharma's $5 Billion Licensing Deal Reshapes China's Lung Cancer Landscape
In a significant development for the Chinese pharmaceutical industry, Akeso Biopharma's anti-PD-1/VEGF-A bispecific antibody, AK112, has been approved for marketing by China's National Medical Products Administration (NMPA). This breakthrough approval not only provides a new treatment option for patients with EGFR-mutant advanced or metastatic non-small cell lung cancer (NSCLC) but also marks a remarkable milestone for the company, which recently secured a lucrative $5 billion licensing deal for the drug.
AK112, marketed as Yidafang, is a humanized IgG1 bispecific antibody that simultaneously targets VEGF-A and PD-1. By competitively blocking the interactions between VEGF-A, PD-1, and their ligands, AK112 exerts potent anti-tumor activity. The drug has previously been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation (CDE) on three occasions, further underscoring its clinical significance.
According to the data presented at the 2024 European Lung Cancer Congress (ELCC), AK112 in combination with chemotherapy demonstrated impressive results in the treatment of EGFR-TKI-experienced, EGFR-mutant advanced non-squamous NSCLC. With a median follow-up of 25.8 months, the objective response rate (ORR) was 68.4%, the disease control rate (DCR) was 94.7%, and the median duration of response (mDoR) was 8.7 months. Notably, the median progression-free survival (mPFS) was 8.5 months, and the median overall survival (mOS) reached 22.5 months, with a 12-month OS rate of approximately 73.7%.
The stellar performance of AK112 in its Phase 2 clinical trials has led to a remarkable licensing deal. In late 2022, Akeso Biopharma granted Summit Therapeutics the exclusive development rights for AK112 in the United States, Europe, Canada, and Japan, in a deal valued at up to $5 billion, including a $500 million upfront payment and tiered double-digit royalties on net sales. This transaction has set a new record for the out-licensing of a domestically developed novel drug from China.
Looking ahead, AK112 has six ongoing Phase 3 clinical trials, including two international, multi-center studies led by Summit Therapeutics and four head-to-head trials against PD-1 monoclonal antibodies. As more data from these trials becomes available, the medical community eagerly awaits the further demonstration of AK112's potential to transform the treatment landscape for patients with EGFR-mutant NSCLC.
This approval and the accompanying licensing deal underscore the growing strength and global recognition of China's biopharmaceutical industry. Akeso Biopharma's success with AK112 serves as a testament to the country's ability to develop innovative therapies that can compete on the international stage and provide much-needed treatment options for patients worldwide.
2026-10-28
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
Tinci Materials Calls Off 2.65 Billion Yuan Project as Electrolyte Giant Shifts Strategy
-
India’s Tariff Cuts Could Lower Agrochemical Costs
-
Japan Tightens Additive Use Standards
-
March Brought a Faster Global Food Rule Cycle
-
Brazil Rewrites the Supplement Rulebook
-
China Moves Lycopene Toward Filing-Based Health Food Management
-
Saudi Aramco Weighs Discounts of Up to $9/Barrel on Oman STS Crude as Freight Costs Surge
-
The Chemical Market Is No Longer Just Raising Prices — It Has Started Stopping Quotations
-
Fertilizer Shock Reshapes Rice Export Decisions
Recommend Reading
-
Wanhua USA Reaches $7.75 Million Settlement in MDI/TDI Antitrust Lawsuit
-
Shandong’s Export Growth Is 2.8%; This Category Is 19%: Shandong Has a Chokehold on the Upstream of Global Manufacturing
-
Shell Qatar GTL Unit Partially Restarts, Enters Spot Market
-
“Oil Sheikhs” Buy Germany’s Chemical Crown: A €14.7 Billion Green Gamble or a Power Play in the Age of Carbon Neutrality?
-
From “10,000-Ton Bet” to “5,000-Ton Test”: Acore’s Polyetheramine Dilemma—Is This a Symptom of Industry Winter or the Prelude to Strategic Retreat?
-
Business Society October 10, 2026 PC Trend Analysis: Volatile with a Slight Bullish Bias
-
FDA Lifts Administrative Stay, Restoring Red No. 3 Ban Timeline for Food and Ingested Drugs
-
Business Society October 10, 2026 Palm Oil Trend Analysis: Volatility
-
Business Society October 9, 2026 Polyester Staple Fiber Trend Analysis: Uptrend Confirmed
-
Business Society Petroleum Coke Daily Review: Overall Downward Trend on August 7, 2026